CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India.
Appl Microbiol Biotechnol. 2012 Apr;94(2):307-21. doi: 10.1007/s00253-012-3967-6. Epub 2012 Mar 6.
Heparin/heparan sulphate glycosaminoglycans (HSGAGs) are composed of linear chains of 20-100 disaccharide units of N-acetylated D: -glucosamine α (1-4) linked to glucuronic acid. HSGAGs are widely distributed on the cell surface and extracellular cell matrix of virtually every mammalian cell type and play critical role in regulating numerous functions of blood vessel wall, blood coagulation, inflammation response and cell differentiation. These glycosaminoglycans present in this extracellular environment very significantly influence the blood coagulation system and cardiovascular functions. Recent studies have investigated the mechanism by which cancer causes thrombosis and emphasizes the importance of the coagulation system in angiogenesis and tumour metastasis. Heparan sulphate/heparin lyases or heparinases are a class of enzymes that are capable of specifically cleaving the (1-4) glycosidic linkages in heparin and heparan sulphate to generate biologically active oligosaccharides with substantially significant and distinct clinical, pharmaceutical and prophylactic/therapeutic applications. Bioavailability and pharmacokinetic behaviour and characteristics of these oligosaccharides vary significantly depending on the origin/nature of the substrate (heparin or heparan sulphate-like glycosaminoglycans), the source of enzyme and method of preparation. Various microorganisms are reported/patented to produce these enzymes with different properties. Heparinases are commercially used for the depolymerization of unfractionated heparin to produce low molecular weight heparins (LMWHs), an effective anticoagulant. Individual LMWHs are chemically different and unique and thus cannot be interchanged therapeutically. Heparinases and LMWHs are reported to control angiogenesis and metastasis also. This review catalogues the degradation of HSGAGs by microbial heparin/heparan sulphate lyases and their potential either specific to the enzymes or with the dual role for generation of oligosaccharides for a new generation of compounds, as shown by various laboratory or clinical studies.
肝素/硫酸乙酰肝素糖胺聚糖 (HSGAG) 由 20-100 个二糖单位组成,这些二糖单位由 N-乙酰基-D: -葡萄糖胺 α (1-4) 与葡萄糖醛酸连接而成。HSGAG 广泛分布于几乎所有哺乳动物细胞类型的细胞表面和细胞外基质中,在调节血管壁、血液凝固、炎症反应和细胞分化等多种功能中发挥着关键作用。这些存在于细胞外环境中的糖胺聚糖对血液凝固系统和心血管功能有非常显著的影响。最近的研究探讨了癌症导致血栓形成的机制,并强调了凝血系统在血管生成和肿瘤转移中的重要性。肝素/硫酸乙酰肝素裂解酶或肝素酶是一类能够特异性切割肝素和硫酸乙酰肝素中 (1-4) 糖苷键的酶,生成具有显著且独特的临床、药物和预防/治疗应用的生物活性寡糖。这些寡糖的生物利用度、药代动力学行为和特征因来源/性质(肝素或硫酸乙酰肝素样糖胺聚糖)、酶的来源和制备方法而异。各种微生物已被报道/获得专利以产生具有不同特性的这些酶。肝素酶被商业用于将未分级的肝素解聚为低分子量肝素 (LMWH),一种有效的抗凝剂。各个 LMWH 在化学上不同且独特,因此不能在治疗上相互替代。肝素酶和 LMWH 也被报道可控制血管生成和转移。本综述列出了微生物肝素/硫酸乙酰肝素裂解酶对 HSGAG 的降解及其潜在作用,这些作用可能是酶特有的,也可能是生成寡糖的双重作用,这已被各种实验室或临床研究证实。